Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Caldesmon as a therapeutic target for proliferative vascular diseases.

Literature DB >> 18855735

Caldesmon as a therapeutic target for proliferative vascular diseases.

Abstract

Caldesmon is a negative regulator of cell proliferation, migration, and metalloproteinase release. Caldesmon function is regulated by multiple kinases, targeting multiple phosphorylation sites. Recently, overexpression of caldesmon has been shown to inhibit neointimal formation after experimental angioplasty, suggesting that caldesmon may be a potential therapeutic target for proliferative vascular diseases.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18855735 PMCID： PMC4322390 DOI： 10.2174/138955708786140981

Source DB: PubMed Journal: Mini Rev Med Chem ISSN： 1389-5575 Impact factor: 3.862

84 in total

1. Phosphorylation of caldesmon by p21-activated kinase. Implications for the Ca(2+) sensitivity of smooth muscle contraction.

Authors: D B Foster; L H Shen; J Kelly; P Thibault; J E Van Eyk; A S Mak
Journal: J Biol Chem Date: 2000-01-21 Impact factor: 5.157

Review 2. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery.

Authors: V Sriram; C Patterson
Journal: Circulation Date: 2001-05-15 Impact factor: 29.690

Review 3. Targeting the protein kinase C family: are we there yet?

Authors: Helen J Mackay; Christopher J Twelves
Journal: Nat Rev Cancer Date: 2007-07 Impact factor: 60.716

4. Phosphorylation of smooth muscle caldesmon by calmodulin-dependent protein kinase II. Identification of the phosphorylation sites.

Authors: M Ikebe; S Reardon
Journal: J Biol Chem Date: 1990-10-15 Impact factor: 5.157

1. Forkhead box O member FOXO1 regulates the majority of follicle-stimulating hormone responsive genes in ovarian granulosa cells.

Authors: Maria K Herndon; Nathan C Law; Elyse M Donaubauer; Brandon Kyriss; Mary Hunzicker-Dunn
Journal: Mol Cell Endocrinol Date: 2016-06-17 Impact factor: 4.102

1 in total

Caldesmon as a therapeutic target for proliferative vascular diseases.

1. Phosphorylation of caldesmon by p21-activated kinase. Implications for the Ca(2+) sensitivity of smooth muscle contraction.

Review 2. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery.

Review 3. Targeting the protein kinase C family: are we there yet?

4. Phosphorylation of smooth muscle caldesmon by calmodulin-dependent protein kinase II. Identification of the phosphorylation sites.

5. Phosphorylation by casein kinase II affects the interaction of caldesmon with smooth muscle myosin and tropomyosin.

6. Modulation of actin mechanics by caldesmon and tropomyosin.

7. Genomic structure of the human caldesmon gene.

8. Dual mechanism of a natural CaMKII inhibitor.

9. Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation.

10. Localization of caldesmon and its dephosphorylation during cell division.

1. Forkhead box O member FOXO1 regulates the majority of follicle-stimulating hormone responsive genes in ovarian granulosa cells.